China’s Sinopharm to test potential COVID-19 vaccine in Brazil

RIO DE JANEIRO (Reuters) – Chinese drug company Sinopharm and Parana state have agreed to launch the fourth major COVID-19 vaccine trial in Brazil and will seek regulatory approval in the next two weeks, the Brazilian partners said on Wednesday.

A trial by Sinopharm would join Phase III trials already announced in Brazil by AstraZeneca, Sinovac Biotech and a Pfizer partnership with BioNTech.


By Pedro Fonseca via Reuters


Read full article here

Share This

Chamber Updates Stay connected with Chamber activities